US Drug Recall Register
Class II · Moderate risk Ongoing Initiated Apr 26, 2023 (3 years ago)

HydrALAZINE HCl Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

What was recalled

HydrALAZINE HCl Injection, USP, 20 mg/mL, 1 mL Single Dose vials, For Intramuscular or Intravenous Use, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs

Recalling firm
Akorn, Inc.
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0809-2023

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Hydralazine recalls

See all
Class II · Moderate risk Ongoing

HydrALAZINE Hydrochloride

Reason Failed Impurities/Degradation Specifications

Sky Packaging NDC 63739-328-10 D-0220-2025
Class II · Moderate risk Ongoing

HydrALAZINE Hydrochloride

Reason Failed Impurities/Degradation Specifications

Sky Packaging NDC 63739-327-10 D-0219-2025
Class III · Low risk Terminated

Hydralazine HCl Tablets

Reason Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6441-61 D-0045-2025
Class II · Moderate risk Terminated

HydrALAZINE Hydrochloride Tablets

Reason an out of specification result obtained during routine stability testing for Impurities. There is a remote possibility that use of this product could cause a medically reversible or transient adverse health consequences.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6440-61 D-0324-2024
Class III · Low risk Ongoing

HydrALAZINE Hydrochloride Tablets

Reason Failed Impurities/Degradation Specifications: Out of Specification (OOS) result in the repackaged product for Related Compounds (Impurities) at the 6-month time point.

Amerisource Health Services LLC D-0320-2024